Cullinan Therapeutics’ (CGEM) Buy Rating Reaffirmed at BTIG Research

Cullinan Therapeutics (NASDAQ:CGEM)‘s stock had its “buy” rating restated by BTIG Research in a report released on Friday, Benzinga reports. They currently have a $40.00 price objective on the stock. BTIG Research’s target price points to a potential upside of 170.09% from the stock’s previous close.

A number of other research analysts have also commented on the company. Wall Street Zen lowered Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 13th. HC Wainwright boosted their target price on Cullinan Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday. Wedbush upped their target price on Cullinan Therapeutics from $39.00 to $42.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. TD Cowen raised Cullinan Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Cullinan Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $33.71.

Cullinan Therapeutics Trading Down 4.1%

Shares of CGEM stock traded down $0.63 during mid-day trading on Friday, reaching $14.81. The stock had a trading volume of 1,715,490 shares, compared to its average volume of 900,974. The stock’s 50-day moving average price is $19.83 and its two-hundred day moving average price is $16.71. Cullinan Therapeutics has a 52-week low of $5.68 and a 52-week high of $23.19. The firm has a market capitalization of $953.17 million, a PE ratio of -4.78 and a beta of 0.02.

Cullinan Therapeutics (NASDAQ:CGEM) last posted its earnings results on Thursday, August 6th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.01). On average, equities research analysts forecast that Cullinan Therapeutics will post -3.08 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Jennifer Michaelson sold 8,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $21.57, for a total transaction of $172,560.00. Following the sale, the insider owned 158,844 shares of the company’s stock, valued at $3,426,265.08. The trade was a 4.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 46,000 shares of company stock worth $922,920 over the last 90 days. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Cullinan Therapeutics

Several large investors have recently made changes to their positions in CGEM. BlackRock Inc. bought a new stake in shares of Cullinan Therapeutics in the 2nd quarter worth approximately $95,289,000. Blue Owl Capital Holdings LP bought a new position in Cullinan Therapeutics during the 2nd quarter valued at approximately $28,039,000. Boothbay Fund Management LLC bought a new position in Cullinan Therapeutics during the 4th quarter valued at approximately $12,803,000. Dimensional Fund Advisors LP raised its stake in Cullinan Therapeutics by 6.7% during the first quarter. Dimensional Fund Advisors LP now owns 906,028 shares of the company’s stock valued at $12,870,000 after buying an additional 57,259 shares during the last quarter. Finally, Boone Capital Management LLC bought a new stake in Cullinan Therapeutics in the second quarter worth $12,828,000. 86.31% of the stock is currently owned by hedge funds and other institutional investors.

Cullinan Therapeutics News Roundup

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: BTIG reaffirms a Buy rating and $40 price target. The target implies substantial upside from the recent trading level and indicates that BTIG continues to see significant value in Cullinan’s pipeline. Benzinga analyst rating report
• Positive Sentiment: Multiple clinical readouts are scheduled for the fourth quarter. Cullinan expects multi-dose velinotamig data in systemic lupus erythematosus at the ACR Convergence conference in November, followed by CLN-978 data in lupus, rheumatoid arthritis and Sjögren’s disease, plus updated CLN-049 data in December. These updates could provide important evidence for the company’s T-cell engager strategy. Cullinan fourth-quarter 2026 milestones
• Neutral Sentiment: Reported short interest was effectively zero. Data as of September 24 showed no reported shares sold short and a zero-day short-interest ratio, suggesting that short selling is not a clear explanation for the recent weakness. The figures may also reflect a reporting anomaly and should be interpreted cautiously.
• Negative Sentiment: Cullinan delayed early-stage arthritis-therapy data until December. The postponement removes a near-term catalyst and appears to have disappointed investors, increasing focus on execution and the timing of the company’s immunology programs. Cullinan delays arthritis-therapy data
• Negative Sentiment: Zipalertinib sentiment remains unsettled. Although Phase 3 lung-cancer results were characterized as strong, investors continue to question the drug’s safety profile and the durability of the bull case. Those concerns have overshadowed the efficacy data and contributed to selling pressure. CGEM stock and zipalertinib safety concerns

About Cullinan Therapeutics

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company’s approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need.

Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.